NVS

Novartis AG Sponsored ADR · NYSE

Sector Health Technology
Industry Pharmaceuticals: Major
Website novartis.com
Employees(FY) 101703
ISIN US66987V1098

Performance

+6.75%

+1.65%

+16.7%

-2.03%

+17.36%

YTD

+22.69%

Profile

Novartis AG researches, develops, manufactures, and markets healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol. Novartis AG was incorporated in 1996 and is headquartered in Basel, Switzerland.

Advanced Technical Analysis

Technical Analysis of NVS 2025-04-17

The stock exhibits a strong bullish sentiment with a Moving Average Score of 100, indicating robust upward momentum, while the Technical Score of 75 further supports this positive outlook. However, the Oscillators Score of 50 suggests a neutral stance, indicating potential consolidation or indecision in the market.

Technical Scores and Rating

Moving Average Score

Oscillator Score

Technical Rating

Stock Analysis of NVS

Stock Rank

Recent News & Updates

2025-03-28 04:55
Analyst Report: Novartis AG(Yahoo Finance)
2025-03-27 00:31
5 Reasons To Buy Regenxbio Right Now(Seekingalpha)
2025-03-26 20:30
Global Radiotherapy Market Expected to Reach $9.62 Billion By 2030 Realizing Growth Due to Technological Advancements(Globenewswire)
2025-03-25 20:00
The Radoff-JEC Group Nominates Three Highly Qualified Candidates for Election to the Atea Pharmaceuticals Board of Directors(Businesswire)
2025-03-25 02:59
Tempero secures $70m to advance addiction treatment candidate(Yahoo Finance)
2025-03-24 20:50
Looking for Stocks with Positive Earnings Momentum? Check Out These 2 Medical Names(Zacks)
2025-03-24 20:45
Watch These 5 AI-Powered Healthcare Bigwigs for Portfolio Gains(Zacks)
2025-03-24 18:47
5 Large Drug Stocks to Watch as Industry Recovers(Zacks)
2025-03-24 14:15
Novartis to present new data at AAN, including seven-year disability outcomes and safety analysis of Kesimpta® in people with relapsing multiple sclerosis(Yahoo Finance)
2025-03-24 11:06
Wasatch Global Value Fund Q4 2024 Commentary(Seekingalpha)
2025-03-24 00:00
Lantheus Holdings: One Blockbuster, Evolving Pipeline(Seekingalpha)
2025-03-22 23:41
Morgan Stanley says Fabhaltas label leaves opportunity for Apellis Empaveli(Yahoo Finance)
2025-03-22 02:10
FDA Approves Novartis Drug for Rare Kidney Disease Treatment(Zacks)
2025-03-22 00:46
Alnylam Gets FDA Nod for Expanded Use of Amvuttra in Cardiomyopathy(Zacks)
2025-03-22 00:26
Pharma Stock Roundup: PFE's Final Haleon Stake Sale, AZN, SNY M&A Deals(Zacks)
2025-03-21 23:36
FDA Approves Expanded Use Of Novartis Rare Disease Drug As Only Treatment For Rare Type Of Kidney Disease(Yahoo Finance)
2025-03-21 20:15
AstraZeneca deepens China investment; Editas loses CFO to Dyne(Yahoo Finance)
2025-03-21 07:37
Novartis receives third FDA approval for oral Fabhalta (iptacopan) - the first and only treatment approved in C3 glomerulopathy (C3G)(Prnewswire)
2025-03-21 00:42
Monte Rosa to focus on prostate cancer only for oncology asset MRT-2359(Seekingalpha)
2025-03-21 00:30
Sanofi Inks $1.9B Deal With Dren Bio to Buy Autoimmune Disease Drug(Zacks)
2025-03-20 21:34
Novartis Reports Updated Positive Data From Phase III SMA Program(Zacks)
2025-03-20 20:26
Novartis builds case for new SMA gene therapy(Yahoo Finance)
2025-03-20 19:42
FDA approves Novartis' Fabhalta for C3 glomerulopathy treatment(Pharmaceutical-business-review)
2025-03-20 19:21
Merck Vs. Bristol-Myers Squibb: Which Pharma Stock Should You Buy(Seekingalpha)
2025-03-20 16:00
Teens death following Sarepta DMD gene therapy underscores a risk seen for decades(Yahoo Finance)
2025-03-20 14:21
Novartis receives third FDA approval for oral Fabhalta treatment for kidney disease C3G(Seekingalpha)
2025-03-20 05:18
Harrow: A Name I Am Accumulating(Seekingalpha)
2025-03-20 01:09
Novartis New Data From Single-Dose Gene Therapy Shows Meaningful Efficacy, Safety In Patients With Spinal Muscular Atrophy(Yahoo Finance)
2025-03-19 21:00
New Novartis Phase III data demonstrate meaningful efficacy and safety results of intrathecal onasemnogene abeparvovec in broad patient population with SMA(Yahoo Finance)
2025-03-19 19:56
Novartis reports Phase III efficacy and safety outcomes of SMA treatment(Yahoo Finance)

Page 1 of 10

previousnext

Disclaimer: The information provided here and on kavout.com is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout makes no recommendations regarding investment decisions based on this information. You are solely responsible for your investments. Please conduct your own research and consult qualified financial advisors before investing. Past performance does not guarantee future results.

NVS

Performance

Profile

Technical Analysis of NVS 2025-04-17

Stock Analysis of NVS

Recent News & Updates

Upgrade to Pro

Pro Features Include: